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Biobanking of patient and patient-
derived xenograft ovarian tumour 
tissue: efficient preservation with 
low and high fetal calf serum 
based methods
Nicolette G. Alkema1,*, Tushar Tomar1,*, Evelien W. Duiker2, Gert Jan Meersma1, Harry Klip1, 
Ate G. J. van der Zee1, G. Bea A. Wisman1 & Steven de Jong3
Using patient-derived xenografts (PDXs) for preclinical cancer research demands proper storage of 
tumour material to facilitate logistics and to reduce the number of animals needed. We successfully 
established 45 subcutaneous ovarian cancer PDXs, reflecting all histological subtypes, with an 
overall take rate of 68%. Corresponding cells from mouse replaced human tumour stromal and 
endothelial cells in second generation PDXs as demonstrated with mouse-specific vimentin and CD31 
immunohistochemical staining. For biobanking purposes two cryopreservation methods, a fetal calf 
serum (FCS)-based (95%v/v) “FCS/DMSO” protocol and a low serum-based (10%v/v) “vitrification” 
protocol were tested. After primary cryopreservation, tumour take rates were 38% and 67% using 
either the vitrification or FCS/DMSO-based cryopreservation protocol, respectively. Cryopreserved 
tumour tissue of established PDXs achieved take rates of 67% and 94%, respectively compared to 
91% using fresh PDX tumour tissue. Genotyping analysis showed that no changes in copy number 
alterations were introduced by any of the biobanking methods. Our results indicate that both 
protocols can be used for biobanking of ovarian tumour and PDX tissues. However, FCS/DMSO-based 
cryopreservation is more successful. Moreover, primary engraftment of fresh patient-derived tumours 
in mice followed by freezing tissue of successfully established PDXs is the preferred way of efficient 
ovarian cancer PDX biobanking.
Intrinsic and acquired resistance to platinum-based chemotherapy is a major obstacle in the treatment 
of patients with epithelial ovarian cancer and more representative experimental models are an important 
step in improving bench-to-bedside transition1. Xenografts derived from cell lines have been widely used 
as a preclinical drug testing platform, however with accumulating scepticism about their clinical predic-
tive value. The development of patient-derived xenograft (PDX) models has been of interest for decades, 
including ovarian cancer based PDX models2–5. Only recently these models are being fully appreciated 
for their possible application in pre-clinical drug testing6. PDX tumours not only accurately phenocopy 
the patient’s tumour from which they are derived at histological level7, but also at expression level8–10, 
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mutational status11 and they preserve copy number variants for multiple generations12,13. Furthermore, 
PDXs resemble their corresponding patient tumour in terms of biological behaviour with engraftment 
rates directly correlated with poorer overall survival and increased metastatic potential3,7,14. Notably, 
response rates of implanted tumour grafts against various conventional agents as well as investigational 
drugs have been reported to correlate with responses of patients15–18.
One of the major issues with PDX models is the varying engraftment rate, with reported latency times 
varying between 1 to 10 months19. Therefore, development of a PDX model will take considerable time. 
Furthermore, it is recommended to maintain the PDX model at a relatively low passage number (< 10) to 
conserve genetic and histological integrity of the original tumour11. Besides this, the histological subtypes 
of ovarian cancer are not equally represented in ovarian cancer patients, with high-grade serous ovarian 
cancer being the predominant subtype among the other three main subtypes, i.e. clear cell, mucinous, 
and endometrioid, and developing a representative model for drug testing will require a large cohort of 
histological identical patients. Considering all the aforementioned factors, the need for reliable and suit-
able preservation methods for ovarian cancer PDX biobanking is indispensable. Such a biobank would 
ideally serve to store patient material and propagated PDX material for reimplantion when required. In 
general, freezing protocols are based upon the usage of fetal calf serum (FCS) (90–95%) combined with 
DMSO (5–10%), but not much is known about take rate and growth using this method. In this study, we 
present our panel of ovarian cancer PDXs together with two methods to preserve human ovarian tumour 
tissues, derived from both patients as well as from their corresponding established PDX model. We have 
tested a 95% FCS/5% DMSO protocol as well as a vitrification-based protocol using 10% FCS and step-
wise increasing concentrations of DMSO, propanediol, polyvinylpyrrolidone and ethylene glycol20. We 
have carefully analysed both methods in terms of take- and growth rate and resemblance to the parental 
patient tumour using immunohistochemistry and copy number alterations.
Results
Patient characteristics and establishment of PDX model. Between April 2011 and December 
2014, tumour tissue from 66 advanced stage (III/IV) ovarian cancer patients was implanted in mice. 
From these, 45 PDXs were successfully established (take rate 68%) (Table  1 and Supplementary Table 
S1). Tumours were collected either during primary surgery (n = 28), interval debulking (n = 12), or at 
relapse (n = 5), and were successfully engrafted in mice, as well as stored using vitrification and/or FCS/
DMSO method. The tumours that did not engraft (n = 21) were obtained from primary surgery in 7 
cases and from interval debulking in 14 cases, suggesting that primary engraftment is more successful 
when tumour tissue is not exposed to chemotherapy compared to tumour tissue obtained from inter-
val debulking (p < 0.003). Furthermore, there was a significantly lower amount of vital tumour cells in 
pieces that did not engraft compared to pieces that successfully engrafted (p < 0.01) (Supplementary Fig. 
S1). Moreover, in 60% of the tumour samples that did not successfully engraft in mice, vital tumour cell 
percentage was below 10%. However, in the established PDX group, only 13% of the tumour samples 
contained less than 10% viable tumour cells.
For proper cross-verification of ovarian cancer patients, an experienced gynaecologic-oncological 
pathologist reviewed histological slides of the tumour to reconfirm the diagnosis. Pathological exami-
nation diagnosed high-grade serous adenocarcinoma for 31 cases, endometrioid carcinoma for 7 cases, 
clear cell carcinoma for 3 cases, mucinous carcinoma in 1 case and a mixed phenotype tumour for 3 
cases (Table  1). Median latency time, defined as time from implantation till first tumour growth was 
observed, was 43 days but varied between histology subtypes (Table 1). After reaching a size of at least 
1 cm3, tumours were harvested and serially transplanted in mice to establish further generations, as well 
as stored using the vitrification and/or FCS/DMSO method (Fig. 1A). After successful establishment in 
first generation (F1), all tumours showed successful engraftment in further generations.
Systematic analysis of biobanking methods. To investigate the preservation methods, we ana-








time in days 
Median 
(range)
Serous 31 31/43 (72%) 82 (14–270)
Endometrioid 7 7/10 (70%) 56 (10–105)
Clear cell 3 3/5 (60%) 21 (16–30)
Mucinous 1 1/2 (50%) 17 (15–21)
Mixed phenotype 3 3/6 (50%) 40 (30–60)
Total 45 45/66 (68%) 43 (10–270)
Table 1.  Successfully established primary ovarian cancer PDXs from May 2011 till January 2015.
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30,36,37,56,67 and 84), 1 endometrioid adenocarcinoma (PDX number 157) and 1 mixed ovarian tumour 
consisting of a teratoma with a borderline mucinous component (PDX number 61), we either thawed 
primary tumour tissue and/or preserved harvested tumours from successfully established PDXs to test 
both preservation methods. Overall take rate for freshly transplanted tumour pieces in the F1 genera-
tion was 27/44 (61%), with tumours from patient numbers 36 and 67 showing growth only for 1 out of 
6 implanted tumour pieces (Table  2). For patient 36 this might be explained by a low amount of vital 
tumour cells in the primary tumour (Supplementary Fig. S3). Harvested tumours were cut into 6 to 
10 pieces for further propagation and storage. PDX tumour tissue from F1, representing each of the 8 
patients, was transplanted in mice as F2 generation using a total of 34 pieces (4–5 pieces per harvested 
tumour), of which 31 grew (91%) (Supplementary Table S2).
In addition, patient tumour specimens were directly frozen using either the vitrification protocol 
(n = 5 patients) or the FCS/DMSO protocol (n = 3 patients) (Supplementary Table S2). Using the vit-
rification method on primary material 4 out of 5 patient samples engrafted successfully, however the 
overall take rate of implanted tumour pieces was 38% (8/21 tumour pieces). The FCS/DMSO method 
was successful for 2 out of 3 patient tumours and showed an overall take rate of tumour pieces of 67% 
(6/9 tumour pieces) (Table 2).
After successful expansion of fresh patient tumours as first generation in mice, tumours were also 
harvested and stored using the vitrification and/or the FCS/DMSO method. With both methods, sub-
sequent establishment of F2 generations was successful in all cases. Overall tumour piece take rates, 
however, were significantly better using the FCS/DMSO protocol when compared to the vitrification 
protocol, achieving take rates of 32/34 (94%) and 16/24 (67%), respectively (p = 0.011) (Table  2 and 
Supplementary Table S2).
Latency period till growth varied between 10 to 270 days for primary tumours and 7 to 104 days 
in F2 generations (Supplementary Table S2). For vitrified primary tumours latency time period of F1 
generation varied from 70 to 320 days, whereas with FCS/DMSO it varied between 18 to 220 days. No 
statistical differences in latency time were found between fresh and/or stored tissues probably due to 
the wide spread of latency time among PDXs. Frozen tissue samples, harvested from already established 
PDXs in F1 showed a latency period in F2 ranging from 35 to 155 days for vitrification and 10 to 115 
days for FCS/DMSO (Supplementary Table S2).
Figure  1B,C show representative growth figures for patient 56 for both freshly serial transplanted 
tumours and for tumours engrafted after storage using both preservation techniques (Fig. 1B,C). After 
Figure 1. Establishment of the ovarian cancer PDX model. (A) Making a single cut in the neck, two 
pieces were subcutaneously transferred to and implanted on either side of the flank of 6–12 weeks old 
female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice. Tumours were measured once or twice a week and after 
reaching appropriate size, tumours were harvested for either direct propagation into a further generation or 
for storage. (B) Tumour growth of fresh implanted tumour tissue from patient 56 and further propagation 
of the tumour (green line) into the second generation (red lines). (C) Tumour growth of stored and 
subsequently thawed and re-implanted tumour tissue from patient 56. Tumour tissue was either directly 
frozen after patients primary surgery (F1) using either the vitrification (green line) or FCS/DMSO (black 
line) protocol. After establishment of a PDX, tumour tissue was harvested from the mouse (F2) and frozen 
using either the vitrification (red line) or FCS/DMSO (blue line) protocol.
www.nature.com/scientificreports/
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engraftment of the primary tumour in three mice, with a success rate of 5/6 tumour pieces, the second 
generation was established using the right-sided tumour from mouse 2 (green line). The second gener-
ation showed a twofold faster growth rate than the first generation with all mice being sacrificed and all 
tumours harvested within 100 days after transplantation (Fig. 1B).
Immunohistochemistry. Morphology of the primary patients’ tumour and of tumours engrafted in 
first and second generations were compared by H&E staining (Fig.  2 and Supplementary Fig. S2–6C). 
Figure 2, displaying a representative series of H&E stainings for patient 56, shows that through increasing 
generations there was a tendency towards a more undifferentiated aspect with loss of characteristic histo-
pathological features and increased nuclear atypia (Fig. 2A,B). Stromal infiltration was observed through-
out serial transplantation. However, human stroma in the tumours was replaced by mouse stroma. This is 
shown by loss of human vimentin staining and gain of expression of mouse vimentin, using two vimentin 
antibodies raised against human and human/mouse, respectively (Fig.  2A,B). Using a monoclonal rat 
anti-mouse antibody for CD31, we demonstrated increased positive mouse CD31 staining of endothelial 
cells lining the vessel walls of PDX tumour tissue when compared to the primary tumour, suggesting 
replacement of human- for mouse vessels. Proliferative rate, as assessed by Ki67, remained high through 
generations as well as in tissue engrafted after storage for both vitrification and FCS/DMSO (Fig. 2A,B). 
Expression of Wilm’s Tumour (WT1), known to be primarily expressed in serous ovarian cancers, was 
seen in all serous patients, and absent in patient 61 (data not shown).
The oestrogen receptor (ER) and progesterone receptor (PR) are known to be frequently expressed in 
serous ovarian cancer and are also associated with improved survival21. Because of the use of a high per-
centage of FCS, we hypothesized that FCS containing growth factors may induce a selection on hormone 
dependent cancer cells and/or changes in signalling pathways. Therefore, we compared the expression of 
ER and PR between the two storage methods in tumour material from three high-grade serous patients 
(37, 56 and 67) and one mixed histology ovarian cancer patient (61). Figure 3 shows the expression of ER 
and PR in tumour tissue from patient 56, tumour tissue from F2 generation of PDX 56, and tumour tis-
sue from F2 generation of cryopreserved PDX 56 generation F1, using either FCS/DMSO or vitrification 
(Fig. 3). PR expression increased in F2 generations compared with the primary tumour. Neither of the 
storage methods influenced the expression levels of ER and PR (Fig. 3). In all 4 PDX models, both con-








Direct propagation 4/6 150 (90–270) 2/2 75 (46–104)
Vitrification 2/6 170 (154–186) — —
36 (Serous)
Direct propagation 1/6 115 6/6 30 (19–39)
Vitrification — — 3/6 55 (35–58)
FCS/DMSO — — 2/2 20
37 (Serous)
Direct propagation 4/6 71 (50–90) 6/6 88 (75–100)
Vitrification 4/6 257 (170–320) 7/9 115 (97–155)
FCS/DMSO — — 6/7 60 (35–78)
56 (Serous)
Direct propagation 4/6 71 (40–192) 3/4 60 (55–70)
Vitrification 1/3 220 2/3 90 (80–100)
FCS/DMSO 3/3 140 (80–220) 6/7 40 (25–70)
61 (Mixed)
Direct propagation 6/6 40 (30–44) 4/4 15 (7–30)
Vitrification 1/3 70 1/3 60
FCS/DMSO 3/3 65 (18–160) 3/3 15 (10–20)
67 (Serous)
Direct propagation 2/6 210 (170–250) 4/4 55 (40–86)
Vitrification 0/3 — 3/3 95 (75–140)
FCS/DMSO 0/3 — 3/3 90 (75–115)
84 (Serous)
Direct propagation 2/4 58 (55–62) 2/4 25 (20–30)
FCS/DMSO — — 6/6 42 (20–59)
157 (Endometrioid)
Direct propagation 4/4 12 (10–14) 4/4 10 (8–15)
FCS/DMSO — — 6/6 25 (14–44)
Table 2.  Take rate of fresh implanted primary tumour pieces and implanted tumour pieces after 
preservation via vitrification and/or FCS/DMSO for all different PDXs. Abbreviations: FCS = Fetal Calf 
Serum, DMSO = Dimethyl sulfoxide, F = generation number, PDX = patient-derived xenograft.
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Copy number alteration analysis. We performed a genome-wide single nucleotide polymorphism 
(SNP) microarray on tumour material from five independent patients (30, 36, 37, 56 and 84) and their 
corresponding PDX tumours of different generations (F1, F2 and F3). Besides these samples, bio-banked 
tumours of PDX 56 using both freezing methods were also included for genotyping analysis. After 
pre-processing and quality control, resulting data were used to calculate copy number alterations (CNAs) 
across the entire human genome and were compared among different samples. Four samples from PDX 
Figure 2. Immunohistochemistry of patient 56 over several generations (F1 (A) and F2 (B)) and after 
established growth after storage using either the vitrification (Vitri) or the FCS/DMSO (FCS) protocol 
on either primary patient tumour tissue (F1) or tumour tissue harvested from previous generations 
(F2). Magnification 10× and for CD31 20× .
www.nature.com/scientificreports/
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30 and 84 did not pass quality control and were not included for subsequent analysis. The pattern of 
CNAs was compared between the primary tumour and different generations of PDX tumours. Grafted 
tumours maintained the CNA pattern of the parental patient tumour (Fig. 4A and Supplementary Fig. 
S7). We observed more accumulation of deletion events in the genome of PDX tumours, which seemed 
to be enhancements of existing genomic aberrations of the primary tumour specimen (Fig.  4A). This 
could be due to the influence of enrichment of human tumour cells after implantation since mouse 
stroma replaced the human stroma as aforementioned.
Furthermore, we also determined the concordance of CNAs between tumours from patients and their 
PDXs (Fig. 4B). A marked heterogeneity was observed among tumours from different patients. However, 
in general, tumours from the same patient and their established PDXs clustered together. Notably for 
some PDXs (PDX 36 and 37), genomic consistency was greater among propagated PDX tumours than 
with the original tumour. This finding again indicates the presence of human stromal and endothelial 
components in the original tumour from patients that are replaced by murine components during serial 
propagation in mice. Taken together, the genomic analyses support the notion that ovarian cancer PDX 
tumours retain their genomic characteristics during propagation over several generations.
Further, no significant copy number changes occurred in the engrafted tumours after storage using 
both methods, compared to freshly propagated tumours (Fig. 4C and Supplementary Fig. S8A and B). 
In addition, CNAs were preserved in tumours and showed significantly high concordance, in either 
stored directly from the patient or from established PDX (Fig. 4C and Supplementary Fig. S8A and B). 
In conclusion, both biobanking methods, FCS/DMSO and vitrification, did not affect the genomic char-
acteristics of engrafted PDX tumours.
Discussion
In this study, we presented our extensive panel of 45 ovarian cancer PDXs. Furthermore, we examined 
two different methods for preserving and thawing of primary ovarian cancer tumour tissue as well as 
PDX-derived tissue from mice. Overall, we achieved a PDX take rate of 68%. After cryopreservation, 
we achieved tumour take rates ranging from 38–67% and 67–94% using either a vitrification or FCS/
DMSO-based cryopreservation protocol, respectively.
Several studies, focusing on PDX models in different types of cancer, mention cryopreservation or 
storage of frozen tumour material, either fresh or from propagated xenografts7,22–25. However, none of 
them reported on take- or growth rates or any other outcome after preservation. One of the early stud-
ies describing a method for cryopreservation of primary tumour tissue was unsuccessful in all primary 
cases using colorectal, pancreatic and gastric tumour tissue26. Only after cryopreservation of already 
xenotransplanted tumours, a success rate of 39% was achieved27. Although not significantly inferior to 
storage of tumour pieces of established PDXs, we also observed less efficiency in engraftment of primary 
frozen patient samples with a longer latency period. Furthermore, this suggests that successful engraft-
ment of frozen tumour tissue is tumour-type dependent.
Sorio et al. were the first to describe a successful cryopreservation method for storage of primary pan-
creatic cancers28. A freezing solution consisting of FCS (30%), DMSO (10%) and RPMI (60%) was used 
and before implantation pieces were soaked in matrigel. Remarkably, take rate in cryopreserved tumours 
was higher compared to freshly implanted tumours. However, overall take rate per implanted tumour 
sample was only 21% for cryopreserved tumours, with a reported time of growth of 1–5 months28. 
Figure 3. Immunohistochemistry of the ER and PR in representative slides of the primary tumour 
tissue of patient 56 (Patient), tumour tissue from F2 generation of PDX 56 (F2), and tumour tissue from 
F2 generation of cryopreserved PDX 56 F1 using either FCS/DMSO (F2:FCS) or vitrification (F2:Vitri). 
Magnification 10× and 40× .
www.nature.com/scientificreports/
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Figure 4. Copy number analysis of ovarian cancer patient tumours and their matched PDX tumours 
using genome-wide SNP array. (A) CNA plots represented the copy number alterations between 
the primary tumour of patient 56, PDX tumour after first engraftment (F1) and PDX tumour after 
3rd engraftment (F3). Genomic gain is indicated in blue and genomic loss is indicated in red over all 
chromosomes. In the upper CNA plot, the average genomic alteration of all three samples is presented in 
a similar manner (blue: amplification and red: loss). Below each CNA plot of each sample, the bar with 
colors represents the allelic events (yellow for loss of heterozygosity (LOH); purple for allelic imbalance). 
(B) Quantitative CNA concordance analysis of tumours of patients and their corresponding PDXs by 
hierarchical clustering. (C) Quantitative CNA concordance analysis of engrafted tumours of patient 56 after 
preservation using both methods compared to freshly propagated tumours by hierarchical clustering. Note 
that the scale bar of the Pearson Value is different for (B and C).
www.nature.com/scientificreports/
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Further improvement was obtained using FCS (90%) with 10% DMSO for cryopreservation of primary 
clinical colorectal cancer specimens, resulting in take rates of 71%29, in line with our results.
The alternative method, vitrification, is adapted from reproductive medicine, where cryopreservation 
of ovarian tissue, embryos and oocytes is an important field of study20,30,31. Using vitrification, cells are 
exposed to different types and concentrations of cryoprotectants in a stepwise manner to avoid extra- 
and intracellular ice crystals formation-induced damage, followed by a fast direct freezing in liquid nitro-
gen30. Till now, this new vitrification method had not been applied for PDX-derived tumour biobanking 
or compared with the established FCS-based freezing method. Although being a more time-consuming 
technique, vitrification of embryos and oocytes has become the method of choice in reproductive med-
icine with successful conception rates in patients32,33.
We have further characterized the fresh and biobanked tumours. We showed that over different gen-
erations histological and proliferative characteristics grossly remained comparable. Also, no differences 
were seen between the two freezing protocols. Replacement of original tumour stroma by mouse stroma 
and takeover of mouse endothelial cells in the vessel lining were seen consistently in all patients after 
first generation engraftment and subsequent transplantation or storage. The loss of human vimentin and 
gain of mouse CD31 suggests stromal infiltration and takeover of vascularization by the murine host. 
This has previously been reported in various types of solid tumours and was shown to occur already in 
an early phase of engraftment after 4–8 weeks34.
Ovarian cancer is known to express both oestrogen and progesterone receptors21. Hormone receptor 
status is dependent on several factors, of which histological subtype is one of them, with the high-grade 
serous subtype expressing at least one of the two receptors in 84%21. Stimulation of especially the ER has 
shown to enhance ovarian cancer cell proliferation35. Furthermore, it has been reported in breast cancer 
xenografts that ER status is an important factor in tumour take rate7,24. Therefore, we wanted to examine 
whether the stimulating growth factors in FCS affected ER and PR expression and thus tumour take rate. 
However, no differences in immunohistochemical ER and PR staining were observed between tumours 
derived from fresh and stored tumour tissue, suggesting that neither storage nor the percentage of FCS 
in the freezing solution influenced the hormone receptor status of these ovarian cancer PDXs.
It has been well established that there is a high concordance between primary tumour and tumours 
taken from various generation of PDXs in term of genomic alterations36,37. However, an accumulation 
of genomic alterations in the PDX compared with the patient tumours was also described7,38. The main 
contributor for these genomic alterations could be the enrichment of human tumour DNA after loss of 
human stromal cells during propagation in mice. A recent whole-genome study of breast cancer patient 
tumours, PDX tumours and their lymphocytes, using exome sequencing and RNA-sequencing analysis, 
showed genomic stability of PDX tumours during serial transplantation in mice39. In alignment with 
previous results, we found the same trend of enhancement of certain genomic aberrations that were pre-
disposed in patient tumour with a lower frequency. Further, the prominent CNA patterns were typically 
maintained in the engrafted tumours after storage using both protocols when compared to freshly propa-
gated tumours. These genotyping results support our immunohistochemically confirmed phenotypic data 
of PDXs tumours, which showed no differences in histological and proliferative characteristics between 
two freezing protocols.
Ovarian cancer PDX models are nowadays well established and examined for their patients’ mimick-
ing potential10,40,41. The next step will be to use these models for development of patient tailored therapy, 
either in pre-clinical drug testing with new targeted drugs or as a model for patients’ personalized ther-
apy decision making36. For logistic purposes and feasibility of these trials, biobanking of tumour tissue 
will be essential. Currently, we implant fresh tumour material in F1, after which harvested tumours are 
stored using the FCS/DMSO method. By doing this, we reduce loss of precious patient tumor material 
and maximize the chance of successful establishment of primary patient material as a PDX. Furthermore, 
since these tumors show high take rates in F2 and relatively fast growth along with recapitulating most 
of the histological and genomic features of patient tumours, we are able to largely expand our biobank 
with high quality reimplantable tumour material. With this protocol as a standard of biobanking, we have 
achieved reproducible take rates for experimental purposes.
In conclusion, we established an extensive panel of 45 ovarian cancer PDXs, reflecting all major his-
tological subtypes. We show that two protocols containing either high or low FCS can be used for bio-
banking of ovarian cancer and PDX tissues. However, the FCS/DMSO-based cryopreservation protocol 
has been proven to be more successful with higher tumour tissue take rates. Primary engraftment of fresh 
patient-derived tumours in mice followed by freezing of successfully established PDXs is the preferred 
way of ovarian cancer PDX biobanking.
Methods
Patients and tumour samples. Ovarian cancer specimens were obtained during surgery, before 
or after 3 cycles of a carboplatin-taxol chemotherapy regime. Before surgery, all patients gave written 
informed consent for their tumour samples to be used for research. Clinicopathological data, obtained 
during standard treatment and follow-up, were stored in an anonymous database managed by two dedi-
cated data managers. This study was approved by the medical ethics committee of the University Medical 
Centre Groningen and carried out in accordance with the approved guidelines and regulations.
www.nature.com/scientificreports/
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Establishing of tumour xenografts. Specimens obtained during surgery were transported in 
transportation media consisting of DMEM containing 10% FCS, 1% penicillin/streptavidin, 2.5 μ g/mL 
Fungizone and 50 μ g/mL Gentamycin on room temperature. Within 5 hours, tumour fragments were cut 
into pieces of ca. 3 × 3 × 3mm using sterile surgical instruments. One piece was snap-frozen in liquid 
nitrogen and another piece was formalin-fixed for later histological examination. Typically, 2 pieces were 
subcutaneously implanted on both sides of the flank of three 6–12 weeks old female NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ mice (internal breed, Central Animal Facility, University Medical Centre Groningen). 
Surgery was performed under sterile conditions in a laminar flow cabinet using sterilized surgical instru-
ments. A single cut was made in the neck of the animal and two pieces were subcutaneously transferred 
to either side of the flank using blunt forceps. Remaining pieces were preserved using vitrification and/
or FCS/DMSO protocol. Mice were kept under pathogen-free conditions in the Central Animal Facility 
(University Medical Centre Groningen) and received sterilized food and water ad libitum. All animal 
experiments were approved by the Institutional Animal Care and Use Committee of the University of 
Groningen (Groningen, the Netherlands) and carried out in accordance with the approved guideline 
“code of practice: animal experiments in cancer research”.
Tumour growth. Upon growth, tumours were measured once or twice a week in two dimensions 
using a slide vernier calliper. Tumour volume was calculated using the equation (width2xlength)/2. 
When tumour size reached > 1 cm3 or animals reached one of the other endpoints as mentioned in the 
Dutch Code of Practice for animals experiments in cancer research (Netherlands Inspectorate for Health 
Protection, Commodities and Veterinary Public Health, 1999), tumours were harvested and put in trans-
portation media, for either direct propagation into a further generation or for storage. Latency time, the 
time till growth was observed, was defined as the time between implantation and the first moment of 
measurable tumour (approximately 70 mm3).
Preservation using vitrification and thawing procedure. Primary tumours and tumours har-
vested from established PDXs were cut into pieces of ca. 3 × 3 × 3mm using sterile surgical instruments 
in a laminar flow cabinet. Sterile 24-well plates were prepared either containing 1 mL of rinse medium 
or 1 mL of either vitrification solution 1 or 2 (VS1 or VS2). Another 24-well plate, containing VS3, was 
prepared on ice. Constitution of different solutions is shown in Supplementary Table S3. All solutions 
were filtered through a sterile 0.2 μ m filter. Each tissue fragment was first incubated in rinse medium at 
room temperature for 5 minutes. Subsequently, pieces were transferred to VS1 and then to VS2 with an 
incubation time of 5 and 10 minutes at room temperature, respectively. Afterwards, pieces were trans-
ferred into VS3 and incubated on ice for 10 minutes. Finally, each piece was transferred into a sterile 
cryotube, snap-frozen in liquid nitrogen and then stored in a liquid nitrogen tank.
For thawing, cryotubes were held in a water bath (37 °C) until melted. In a laminar flow cabinet, 
sterile 24-well plates were prepared with wells containing either 1 mL of thawing solution (TS) 1, 2, 3 or 
4 (Supplementary Table S3). All solutions were filtered through a sterile 0.2 μ m filter. Tissue fragments 
were placed in TS1 for 2 minutes at room temperature. Then pieces were transferred for 5 minutes in 
TS2, TS3 and TS4, respectively. Finally, pieces were kept in transportation media at room temperature 
until implantation.
Preservation using FCS/DMSO and thawing procedure. After harvesting and dissecting, primary 
tumours and tumours harvested from established PDXs were cut into pieces of ca. 3 × 3 × 3 mm3 using 
sterile surgical instruments in a laminar flow cabinet. Pieces were transferred into sterile cryotubes con-
taining 1.5 mL 95%FCS/5% DMSO. Cryotubes were put in a freezing container containing isopropanol, 
placed in an − 80 °C freezer overnight and transferred to liquid nitrogen storage the next day.
For thawing, cryotubes were held in a water bath (37 °C) until melted. In a laminar flow cabinet 
pieces were dipped into FCS for 2 minutes and were then transferred into transportation media at room 
temperature until implantation.
Immunohistochemistry. For immunohistochemistry, 4 μ m sections were cut from paraffin-embedded 
tumour tissue and these sections were mounted on amino-propyl-ethoxy-silan-coated glass slides. 
Morphology of tumours was assessed using staining with haematoxylin and eosin (H&E) and immunohis-
tochemical staining for Ki67, CD31, WT1, Vimentin (anti human clone, anti human/mouse), ER and PR. 
Antigen retrieval methods, primary antibodies and detection methods are presented in Supplementary 
Table S4. Colon, kidney and tonsil served as positive controls for vimentin, WT-1 and CD31, respectively. 
Oestrogen- and progesterone- receptor positive breast cancer served as positive controls for ER and PR 
staining. All slides were deparaffinised in xylene. Endogenous peroxidase was blocked by incubation with 
0.3% hydrogen peroxidase for 30 minutes. Lastly, staining was visualized by DAB and counterstaining 
was performed with haematoxylin. ER and PR status was considered positive if at least 1% of tumour 
nuclei stained positive, according the official cut-off determined by the American Association of Clinical 
Oncology (ASCO)42. To obtain more information about the percentage of tumour cells in tumour pieces 
implanted, formalin-fixed tumour pieces obtained at the time of surgery of patients, were stained for 
H&E and used as a representative for implanted pieces. Percentage of tumour cells was scored using 
a 10× magnification, scoring 3 fields of interest, by two independent observers. A mean percentage of 
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tumour cells was calculated and differences between established and non-established PDXs was calcu-
lated using an unpaired two-tailed Student’s t-test.
DNA Isolation of Patient and PDX tumours. Representative frozen blocks of each patient tumour 
and their corresponding PDX tumours of different generation, were retrieved for DNA extraction. 
Histological slides from the frozen tissue were taken for quantifying amount of vital tumour cells. Frozen 
sections of 10 um were cut with periodic 4 μ m sections for H&E staining. For some samples, slides 
were macro-dissected to obtain > 85% neoplastic cells. DNA of all samples was isolated using standard 
salt-chloroform extraction and isopropanol precipitation. In the end, precipitated DNA was re-suspended 
in Tris-EDTA buffer (10 mM Tris; 1 mM EDTA, pH 8.0). Genomic DNA was amplified in a multiplex 
PCR according to the BIOMED-2 protocol, to check the DNA’s structural integrity43.
SNP array-based genotyping. Genome-wide single nucleotide polymorphism (SNP) genotyping 
for 5 independent patients (30, 36, 37 and 56 and 84) along with their corresponding PDX tumours 
was performed on Illumina HumanOmniExpressExome8R BeadChip containing over 900,000 markers. 
Genotypes were called with the standard algorithm provided by Illumina and implemented in Genome 
Studio software with Genotyping module. All the samples were passed the inclusion quality control (QC) 
criteria including the limit of not > 5% of missing genotyping. Additionally, SNPs of samples derived 
from the patient and the corresponding PDX tumours were also compared with SNPs of normal leuco-
cytes of a healthy blood donor. In addition, NSG mouse tail and liver DNA was included on the same 
SNP array as technical controls to check the specificity and cross-reactivity of the array. Further advanced 
analysis was performed with Nexus Copy numberR software (BioDiscovery) using standard SNPs fre-
quency significance testing and enrichment analysis to generate CNA profiles. Moreover, quantitative 
CNA correlative analysis of patients and corresponding PDXs were performed as described previously44. 
Briefly, processed array data were binned into numerical integer value ranging from 1 to 5 for each of 
the quality controlled passed SNP probes (n = 906411), where 1 and 2 indicated copy number losses, 
whereas 4 and 5 were defined as calls for copy number gains. Subsequently, a copy number call matrix 
was formed and hierarchical clustering was performed with the use of Pearson correlation metrics and 
average linkage to reveal similar clusters. All the computations and heatmap generation were performed 
in the R Statistical Environment (R version 3.1.1, R Development Core Team, foundation for Statistical 
Computing, Vienna, Austria).
Statistics. All statistical analyses were performed using GraphPad version 5.01 (GraphPad Software, 
http://www.graphpad.com). Significance between take rates was compared with the Fisher’s exact test. 
Differences between established and non-established PDXs was calculated using an unpaired two-tailed 
student’s t-test. For all tests, P values < 0.05 were considered statistically significant.
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